Integrin-linked kinase (ILK) in combination molecular targeting.
Edwards
Lincoln A
LA
Advanced Therapeutics, BC Cancer Agency and Research Centre, Department of Pathology & Laboratory Medicine, The University of British Columbia.
Shabbits
Jennifer A
JA
Bally
Marcel
M
Dedhar
Shoukat
S
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002465:Cell Movement; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000201:enzymology / Q000473:pathology / Q000628:therapy*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D015398:Signal Transduction; D000099200:Scaffold Protein ILK
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D017346:Protein Serine-Threonine Kinases; D000099200:Scaffold Protein ILK